E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
infective endocarditis |
Endocardite infectieuse |
|
E.1.1.1 | Medical condition in easily understood language |
infective endocarditis |
Endocardite infectieuse |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000667 |
E.1.2 | Term | Acute and subacute infective endocarditis in diseases classified elsewhere |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To visually assess the detectability of cardiac and extracardiac foci in association with infective endocarditis (IE) on native or prosthetic valve by 68Ga-DOTATOC PET/CT |
Évaluer visuellement la détectabilité des foyers cardiaques et extracardiaques en lien avec une endocardite infectieuse (EI) sur valve native ou prothétique par la TEP/TDM au 68Ga-DOTATOC |
|
E.2.2 | Secondary objectives of the trial |
1. Quantify the uptake of 68Ga-DOTATOC at the site of infection by measuring the Standard Uptake Value (SUV) and the relationship with blood activity 2. Compare the results of 68Ga-DOTATOC PET/CT with those of 18F-FDG PET in terms of visual and quantitative analysis on whole body scans. 3. Compare the results of 68Ga-DOTATOC PET/CT with those of 18F-FDG PET, in terms of visual and quantitative analysis of cardiac step examinations.
|
1. Quantifier par la mesure du Standard Uptake Value (SUV) et des rapports avec l’activité sanguine, la captation du 68Ga-DOTATOC au niveau des foyers infectieux 2. Comparer les résultats apportés par la TEP/TDM au 68Ga-DOTATOC à ceux apportés par la TEP au 18F-FDG, en termes d’analyse visuelle et quantitative sur les examens du corps entier. 3. Comparer les résultats apportés par la TEP/TDM au 68Ga-DOTATOC à ceux apportés par la TEP au 18F-FDG, en termes d’analyse visuelle et quantitative sur les examens du pas cardiaque.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Adult having received full information on the organization of the research and having signed informed consent. - Participant hospitalized for definite AR according to the modified Duke criteria (Li), on native or prosthetic valve, referred for 18F-FDG PET/CT by the Cardiology and Infectious Diseases departments
|
- Personne majeure ayant reçu l’information complète sur l’organisation de la recherche et ayant signé son consentement éclairé. - Participant hospitalisé pour EI certaine selon les critères modifiés de Duke (Li), sur valve native ou prothétique, adressé pour une TEP/TDM au 18F-FDG par les services de Cardiologie et de Maladies infectieuses
|
|
E.4 | Principal exclusion criteria |
- Participant with a formal or relative contraindication to 68Ga DOTATOC PET/CT and/or 18F-FDG PET/CT - Impossibility to perform a 68Ga-DOTATOC PET scan (agitated, confused patient...). - Inability to schedule 68Ga-DOTATOC PET/CT the day after 18F-FDG PET/CT. - Participant treated with a somatostatin analogue. - Participant with Cushing's syndrome - Pregnant, likely to be pregnant or breastfeeding |
- Participant ayant une contre-indication formelle ou relative à la réalisation d’une TEP/TDM au 68Ga DOTATOC et/ou d’une TEP/TDM au 18F-FDG - Impossibilité de réaliser une TEP au 68Ga-DOTATOC (patient agité, confus...). - Impossibilité de programmer l’examen TEP/TDM au 68Ga-DOTATOC le lendemain la TEP/TDM au 18F-FDG. - Participant traité par un analogue de la somatostatine. - Participant atteint d’un syndrome de Cushing - Femme enceinte, susceptible de l’être ou en cours d'allaitement |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Presence of a visually detectable 68Ga-DOTATOC uptake zone in the cardiac and extra-cardiac foci. |
Présence d’une zone de captation de 68Ga-DOTATOC détectable visuellement au niveau des foyers infectieux cardiaques et extra cardiaques. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At centralized imaging at the end of the study |
Au moment de l'imagerie centralisée à la fin de l'étude |
|
E.5.2 | Secondary end point(s) |
1. Quantitative measurement(s) of 68Ga-DOTATOC uptake at the site(s) of infective endocarditis by Standard Uptake Value (SUV) and also by relationships with blood SUVs. 2. Results of visual and quantitative analysis of 68Ga-DOTATOC PET/CT and 18F-FDG PET scans on whole body examinations. 3. Results of visual analysis and quantitative analysis of 68Ga-DOTATOC PET/CT and 18F-FDG PET on cardiac step examination. |
1. Mesure(s) quantitative(s) de la fixation de 68Ga-DOTATOC sur le(s) foyer (s) d’endocardite infectieuse par le Standard Uptake Value (SUV) et aussi par des rapports avec les SUV sanguins. 2. Résultats de l’analyse visuelle et de l’analyse quantitative des TEP/TDM au 68Ga-DOTATOC et des TEP au 18F-FDG sur les examens du corps entier. 3. Résultats de l’analyse visuelle et de l’analyse quantitative des TEP/TDM au 68Ga-DOTATOC et des TEP au 18F-FDG sur l’examen du pas cardiaque. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At centralized imaging at the end of the study |
Au moment de l'imagerie centralisée à la fin de l'étude |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |